Contract Research and Manufacturing Services over the last couple of decades have changed the way how Pharma and Biotechnology industries have been functioning. The answer to this change is clearly visible in the way this industry has grown in the period. CRAMS, as a service, is primarily research and manufacturing outsourcing and delivery models offered by CROs (Contract Research Organizations) and CMOs (Contract Manufacturing Organizations).
Some of the major factors that have attributed to the evolution of this outsourcing model in research and manufacturing spaces include – Burgeoning research and development costs, Decreasing productivity as a result of greyish outcome possibilities, Lack of manufacturing capacity and resources etc. The numbers says it all. As of 2018, over 60% of all Pharma related manufacturing and research were outsourced.
CRAMS – The Indian Story
Pharmaceutical manufacturing and research have always been topics of debate as a result of their shear nature, which attract stringent regulation and close scrutiny form policy makers and industry regulators.
This industry makeover has evidently highlighted the rise of Indian CRAMS organizations, which have emerged as front runners for API manufacturing and the delivery of intricate chemistry services. Additionally, the continued economic crunch along with the unremitting pricing pressure and pro-generic agenda are driving Pharma companies to leverage the strengths of Indian Pharma manufacturers.
As more and more Pharma companies looking to drive growth, while mitigate the effects of the industry challenges, seeking services of contract manufacturers. India, South Africa, South East Asia is witnessing a steady rise in organizations offering such services. India alone is looking at a compounded year or year growth of 17 to 18 percent growth in Pharma contract manufacturing and research industry.
On a reflective note, the emergence of Indian CRAMS is inevitable for it has a long and successful history in knowledge intensive industries such as IT, Technology etc. In addition to this, India has the largest bracket of professionals who are proficient in English and highest no of chemistry and manufacturing graduates entering the workforce every year. Furthermore, India has the highest number of FDA approved manufacturing sites outside India and the number is over a hundred as of year 2019. Quality delivery of CRAM services with value on prices have definitely let to India being among the top destinations for manufacturing and research services in Pharma.
For any businesses to sustain and flourish, strategic cost transformation while delivering commercial value to customers is a must. CRAMS is exactly doing that for its clients from across the globe. India, as a CRAMS destination has grabbed on to the opportunity bandwagon without a miss and is expected to take strides northwards from here.